This study was not targeted for elderly NSCLC patients (median age of enrolled patients was 57 years); however it showed that patients in whom an EGFR mutation has been identified will benefit most from first-line therapy with gefitinib [30]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.